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E stablishing an effective therapeutic regimen in cases of severe hyper- 
tension continues to be a highly individ- 
ualistic process of balancing side effects 
against blood pressure response. Sym- 
Ijathetic blocking agents, needed in most 
cases of severe hypertension, often disable 
the patient by causing an orthostatic hypo- 
tension as the price he must pay for a 
lxtrt ix1 reduction of recumbent blood pres- 
sure. 
During the past several years, a new an- 
[ihypertensive agent, 2-(2,6-dichlorphenq-l- 
;tmine)-2-imidazoline hydrochloride (Cata- 
Ix-es), has been under clinical study.’ The 
mode of action of this drug has not yet 
been defined,” but it has been shown to be 
effeclive and relatively safe, with drowsi- 
ness as its major side effect. Most impor- 
tant, the ne\v agent is reported to lower 
recumbent and standing blood pressures 
equallv well throughout the day, without 
the Gide ditlrnal variations that induce 
excessive orthostatic hypotension whell 
the patient rises in the morning, but it 
fails to prevent nocturnal recumbent h!,- 
pertension. Although metabolic side effects 
from Catapres have not been noted ill 
clinical reports, a slight diabetogenic ten- 
dencv has been observed in some species 
of a&als.3 
The study reported here was tlesignctl 
toward three specific objectives: (1) to 
test the agent aIone in subjects with lniltl 
hypertension in order to examine its rc- 
ported ability to lower recumbent blood 
pressure without creating postural hyl)o- 
tension; (2) to test long-term efficnc~- and 
acceptability of the agent for severe11 
hypertensive patients intolerant of COIP 
ventional sympathetic blocking agents; 
(3) to evaluate the frequency and accept- 
ability of various side effects and to es:m1- 
ine the drug’s effects on liver and henlato- 
poietic function and 011 carbohydrate 
metabolism. 
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Methods 
Sisteeu patients, ranging in age from 27 
to 65 years, were studied. The)- were 
divided into two groups on the hasis of 
relative severit). of hypertension. Group 1 
included 6 patients with mild blood pres- 
sure elevation, who had recorded their 
l)lood pressure at home for several weeks 
preceding the drug trial. These patients 
were given Catapres alone for ;i period of 
one month, the studies being- directed 
chiefi!. at the effects of the drug o11 carbo- 
h~drnte n~etahnlisn~. Ckoup 2 coniprisecl 
the remaining 10 patients, \vho had had 
sex-et-e postural hypotension or Lvere other- 
xvise refractory to treatment with the 
~1sua1 sympathetic blocking agents. Hack- 
ground diuretic therapy was maintained 
in all these patients, who were treated with 
(‘atapes alone for periods of 5 to 11 
months. -111 the patients Lvere admitted 
to the Clinical Research Tinit of the lini- 
versitl of hIichigan Hospital for the 
initiation of C‘atapres treatment and were 
discharged in 5 to 6 days. 
(~‘arboh~.drate tolerance was tested in 
subjects helongilig to Group 1 iis follob5. 
l’rior to hospital adltlission they \vere 
placed 011 a 300 (;m. c-nrboh!.dr;lte cliet 
for three tla)x. ;jfter admission, the to- 
butamide tolerance test and the illtr,l- 
venous glucose tolerance test were l)er- 
formed. Then an oral test dose of Catapres, 
0.150 lllg., xvas given and the effects OII 
blood pressure were noted. Based OII the 
response ohserved, a11 qpropriate trcat- 
Inent regimen nas established and the 
tolt~utaniitle test was then repeated 011 
the fourth or fifth day of therapy. iI1 tht 
hospital. The individual’s glucose toler- 
mcc \V;IS re-esanlined on the secontl da\ 
of illpaticrlt treatment a11t1 ;lt the end of ;I 
Illonth of outpatient trentnlent with (‘ata- 
p-es, three da)5 after the pre~mratoq~ rl iet 
hkitl been reinstituted. The intraverlous 
test dose \vas administered ill the rnorltir~g 
in the f:lsting state, two hours after tlruK 
ingestion. 
The Inore severe]\- h!-pertensive sut)- 
jects lIelonging to Group 2 nere handled 
;Ls follows. AAfter other ;tlitih?,l’ertensivc 
tlrugs, except diuretics, hiIt heen discon- 
tinued, m oral test dose of (‘atapes \\‘;Is 
adnlinistered and suhsecluctlt dosqc ill 
1 96 96 
2 83 80 
3 92 80 
4 82 78 
5 80 82 
6 88 75 
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*Fasting blood sugar drawn 2 hours after oral administration of drug. Test dose of drug was 0.150 mg.  
I Ii \~~lue expresses the slope of disappearance ol the glucose solution (25 mg.  per kilogram) injected at time “0”. Samples taken at 
10. LO. 30, 40, 50. and 60 minutes. A negative change in 6 value denotes a slower rate of remtwal of administered glucose. Changes 
a)bsrrved are within the limits of normal variation. 










On USZ~ drug therapy* 
G uanethidine 
7 250/ 140 
8 250/l 60 
9 260/170 
I 0 250/l 40 






Outpatient UP Daily Outpatient BP Duration Daily 
dose -- ~_..__--__- cn Calapres dose 
(mg.) (mu.) (mq.) 
Recumbent Standixf Recumbent Standing 
190/135 lOO/ 70 100 178/030 192/140 7 0.900 A.M. syncope (Lmstipatiun 
232/123 116/ 68 75 192/128 192/132 7 0.900 A.hf. syncope Constipation 
190/100 160/100 50 146/ 94 l?O/ 90 10 0.900 Diarrhea 0 
230/130 160/100 100 232/l 23 198/128 5t 1.200 A.M. syncope 1) 
217/l 13 208/l 30 100 152/ X6 15oj 120 10 0.400 Kane 0 
2uo/ 130 170/l u4 1.500 134/ 88 l42j 94 11 0.500 A.M. qncope Drowiness 
24U/llO 180/124 1.500 184/102 167/108 1 u 0.500 Dizziness Drowsiness 
186/l/109 174/120 1.500 180/100 192/108 11 1.200 None Kane 
198/113 160/l 14 2 ( 000 164/104 146/104 7 0.525 Fatigue Kane 
Usual drzzg Catapres 
Depression Iione 
476 Smet et nl. 
.4m. Heurt 3. 
.4pril, 1969 
1.V TOLBUTAMIDE TESTS 
N = 6 patients 
x, 
\. BEFORE CATAPRES 
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Fig. 1. Response to tolbutamide before md after 
Catapres. Vertical bars indicate standard error of 
the mean for each observation. See text for details. 
the hospital was adjusted to bring about 
a maximal blood pressure reduction within 
the patient’s tolerance to side effects. The 
patients were then followed in the out- 
patient clinic at monthly intervals. They 
continued to take their diuretic drugs 
without change, but their dosage of Cata- 
pres was readjusted in accordance with 
the blood pressure as recorded at home and 
in the clinic. 
Results 
The first oral test dose of 0.150 mg. of 
Catapres regularly lowered the blood 
pressure of patients in Group 1, the aver- 
age decline being -4O/-228 mm. Hg re- 
cumbent and -35/-16 mm. Hg standing 
(Table I). The maximum decline occurred 
between the second and third hour, with 
offset of action at four to six hours. At the 
end of one month, the drug in the original 
dose appeared to lose some of its anti- 
hypertensive effectiveness. 
These patients were studied primarily 
lo evaluate the short-term effect of the 
drug 011 glucose tolerance. The metabolic 
tests were applied at the time interval 
when a slight hyperglycemic influence 
had been noted in the dog studies.’ Tahlc 
11 shows that the drug had no effect on 
the fast-ing blood sugar or on the intra- 
venous glucose tolerance test. The irl- 
f-luence of the drug on insulin release was 
studied using the tolbutamide test. There 
\\ras HO il~dication of an\. consistent clin- 
betogenic trend which inight be attribute(l 
to the drug (Fig. 1). 
I>ong-lt:rm c;ffPi-ts. i\fter 5 to 11 llloiltlls 
of therap). with Catapres aittl a diuretic., 
most Ijatients achieved :L blood pressure 
level coluparable to or better than that 
recorded w:ith prior conventional ar~t i- 
hypertensive treatment. Dosage of the 
llern drug was gradually increased as sitlc 
effects wore off. A dose of 0.5 to 1.2 iiig. 
dail>r served to replace such other agents 
;LS al~~ha-inethyldoI~a (1.5 to 2.0 Grn. 
daily) CJr guaiie~hk~iile (50 to 100 111~. 
daily), with respect to maintaining similar 
blood pressure levels (Table III). Dis- 
abling postural hypotension, occurring with 
the previous regimens iit Patients 7 and S, 
were nluch less apparent 011 Cataprcs at. 
approxilnatel>~ the same levels of recunl- 
bent blood pressure. Blood pressure con- 
trol was sonlewhat erratic; home blood 
I,ressurcs were generally lower than tht: 
clinic readiligs, taken two hours after in- 
gestioll of the morning dose of drug. 
J’atients 9, 11, l.?, and 16 derived clear 
benefit from the conversion to Catapres. 
The other patients had generally lower 
home blood pressures, but they were plot 
necessarilv better controlled on the new 
regimen. ‘l’hese cases were chosen because 
their blood pressure was refractory to 
prior sympathetic blocking agents, or 
they were disabled by orthostatic hype- 
tension. 1 t is therefore not surprising that 
the new drug did not benefit all the IX- 
tients. 
Side efl~ts. The 11~0s~ commo11 reaction 
was drowsiness which was usually transien I 
and did not cancel the patient’s abilitv IO 
mobilize his attention to sudden crjses. 
1)rowsiiiess became less eviclent with (‘OII- 
tinued use of the drug, but initially it \\-a~ 
the chief limiting factor to the size of dose 
which the patient would ;tccept. At Ilight, 
ho\\-ever, this side effect I)ecnnle ;t(lv;tI\- 
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tageous, sirlce a larger dose at bedtime 
resulted in good sedative effects and ap- 
peared to exert some influence on the 
morning blood pressure reading. Dry mouth 
was a minor complaint in most cases; con- 
st ipntion was easily controlled by laxn- 
t ives. 
n larked bradycardia was noted 0111~. 
occ;~sionally in our series and seemed quite 
\r;u-inble. One patient, Ko. 13, taking 0.6 
111x. ;L da>., telephoned to report that his 
lmlse had falle11 to 42 beats per minute 
but was regular. An electrocardiogram 
taken one-half hour later showed a sinus 
rhythm with a rate of 66. 
III the majorit?. of patients, after 6 
111o11ths or Illore of treatment, the side 
effects were greatly diminished and rarely 
disabling, although the effects on blood 
pressure reu1ainet1, as evidenced by a 
pro1npt rise ill blood pressure during a 
brief substitution of a placebo for the 
active drug. None of the patients OII long- 
term treatnrent, 111ost of whom had been 
ro11\:erted fro111 conventional n1edication 
because of side effects, elected to discon- 
ti11ue (‘atapres when given this option. 
No evidenc*e of progression of the cardiac 
or renal complications of their disease was 
noted. The fasting blood sug-nr at the end 
of the observation period was unchanged 
frolll the pretreatn1ent values. 
Real, hepatic, and hematopoietic func- 
tion R’~S unchanged for periods of treat- 
111ent up to 11 months, as judged by serial 
detcrminatio11 of blood ureanitrogen (BUN), 
seru111 glutamic pyruvic transaminase 
(SGI’T), alkaline phosphatase, hemato- 
c.ri(, he1noglobin, and leukocyte and dif- 
ferential cc,11 counts. 
Discussion 
To achieve general usage among current 
;tr1tihppertensive agents, a drug must be 
shown to be safe and continuously effec- 
tive iu reducing blood pressure. Catapres 
fulfills the criteria of long-term effective- 
ness .znd no long-term toxicity developed 
in 10 patients observed for a median period 
of 9 months. While the short-term low- 
dosage study detailed in Table 1 suggests 
that alone the drug loses some of its initial 
effectiveness, our later experience giving 
(‘atapres in c-ombination with diuretics 
indicates that as side effects become less 
prominent dosage may have to be in- 
creased, but that eventually one reaches 
a stable dosage level which maintnins anti- 
hypertensive effectiveness. ~1 potential nd- 
vantage of this agent over sympathetic 
blockers is that it does not interfere with 
postural reflexes. The chief disadvantage 
is that it is not as potent or as continuously 
effective as guanethidine, for esample. 
For these reasons we believe Catapres 
will be useful in the management of se- 
lected cases of moderately severe hyper- 
tension, particularly where sl-mpathetic 
blockers are needed, but cause severe 
postural hypote11sion. 
Summary 
The drug 2-(2,6-dichlorphenylamine)-2- 
imidazoline hydrochloride, available as 
Catnpres, was given to 16 patients with 
established hypertension. Six patients were 
studied for one mouth to detect abnor- 
malities in carbohydrate metabolism. Xorle 
were found. Ten severely hypertensive pa- 
tients were maintained for front 5 to 11 
months on Catapres and diuretics. 
III a single dose, Catapres invariably 
lowered the blood pressure significantly-, 
but without producing orthostatic hype- 
tension. The maximum effect occurred be- 
tween 2 aml 3 hours after ingestion of the 
drug. The duration of drug action was 4 
to 6 hours. 
In long-term treatment of ten patients, 
Catapres, combined with a diuretic, proved 
to be as effective as a diuretic plus guane- 
thidine or Aldomet, which the patients had 
previously been taking. A dose of 0.400 to 
1.200 mg. of Catapres was equivalent to I .5 
to 2.0 C;rn. of Aldomet or 50 to 100 mg. 
of guanethidine. 
The chief side effect of the drug was 
drowsiness, but this was not incapacitating, 
it did not require cessation of treatment, 
and it becatne less prominent with the 
passage of time. In patients who had es- 
perienced severe orthostatic hypotensiou 
on other drug regimens, the condition was 
considerably relieved by Catapres. NO 
signs of toxicity were noted, as judged by 
carbohydrate tolerance, BUN, SGPT, al- 
kaline phosphatase, and hematologic de- 
terminations. 
47x Smrf ct trl. 
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